Renal Cancer - Results from #1720

Effects of race and socioeconomic status on treatment for localized renal masses in New York City. December 13, 2021

Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer - A multicenter population-based cohort study. December 10, 2021

Novel emerging biomarkers to immunotherapy in kidney cancer. December 10, 2021

Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. December 9, 2021

Automated Classification of Papillary Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma Based on a Small Computed Tomography Imaging Dataset Using Deep Learning. December 9, 2021

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. December 8, 2021

Identification of SOX6 and SOX12 as Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma: A Retrospective Study Based on TCGA Database. December 8, 2021

Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. December 7, 2021

The Identification of a Tumor Infiltration CD8+ T-Cell Gene Signature That Can Potentially Improve the Prognosis and Prediction of Immunization Responses in Papillary Renal Cell Carcinoma. December 7, 2021

Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC. December 6, 2021

A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. December 6, 2021

Prognostic value and immunological role of AXL gene in clear cell renal cell carcinoma associated with identifying LncRNA/RBP/AXL mRNA networks. December 3, 2021

Prediction of post radical nephrectomy complications based on patient comorbidity preoperatively. December 3, 2021

ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. December 2, 2021

Novel cut-off values of time from diagnosis to systematic therapy predict the overall survival and the efficacy of targeted therapy in renal cell carcinoma: A long-term, follow-up, retrospective study. December 2, 2021

Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature. December 1, 2021

Comprehensive analysis of ceRNA networks to determine genes related to prognosis, overall survival, and immune infiltration in clear cell renal carcinoma. December 1, 2021

Targeted Quantification of Carbon Metabolites Identifies Metabolic Progression Markers and an Undiagnosed Case of SDH-Deficient Clear Cell Renal Cell Carcinoma in a German Cohort. November 30, 2021

Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. November 30, 2021

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma November 29, 2021

Page 87 of 456